Cantor Fitzgerald analyst Olivia Brayer raised the firm’s price target on Vertex Pharmaceuticals to $380 from $370 and keeps an Overweight rating on the shares. While the stock has run up quite a bit, Cantor stills think there’s potential upside as there are more pipeline updates over the next few months, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $408 from $399 at Barclays
- Vertex raises FY23 CF product revenue view to about $9.85B
- Vertex Pharmaceuticals reports Q3 EPS $3.98, consensus $3.97
- Fly Insider: Barnes Group, Palo Alto among week’s notable insider trades
- Notable companies reporting after market close